Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC trimmed its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 89.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,959 shares of the medical technology company's stock after selling 412,342 shares during the period. Squarepoint Ops LLC's holdings in Alphatec were worth $468,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Comerica Bank boosted its holdings in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the period. Quarry LP increased its holdings in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares during the period. Lazard Asset Management LLC bought a new stake in Alphatec during the 4th quarter valued at $76,000. AlphaQuest LLC purchased a new stake in shares of Alphatec in the 4th quarter worth $80,000. Finally, State of Wyoming bought a new position in shares of Alphatec during the 4th quarter worth $86,000. 66.35% of the stock is currently owned by institutional investors.

Insider Activity

In other news, COO Scott Lish sold 55,375 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $13.00, for a total value of $719,875.00. Following the sale, the chief operating officer now directly owns 771,645 shares of the company's stock, valued at $10,031,385. This represents a 6.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Craig E. Hunsaker sold 186,122 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total transaction of $2,296,745.48. Following the transaction, the executive vice president now owns 1,463,896 shares of the company's stock, valued at $18,064,476.64. This represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 267,375 shares of company stock valued at $3,333,593. Company insiders own 20.90% of the company's stock.

Alphatec Stock Performance

NASDAQ:ATEC traded up $0.29 during trading hours on Friday, hitting $12.73. 1,224,032 shares of the company were exchanged, compared to its average volume of 2,043,113. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -9.95 and a beta of 1.10. The company's 50 day moving average price is $11.52 and its 200-day moving average price is $10.77.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. The company's quarterly revenue was up 22.2% on a year-over-year basis. As a group, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ATEC has been the subject of several recent research reports. Wall Street Zen upgraded Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.